These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15184107)

  • 1. Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.
    Leriche L; Diaz J; Sokoloff P
    Neurotox Res; 2004; 6(1):63-71. PubMed ID: 15184107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.
    Sokoloff P; Leriche L; Diaz J; Louvel J; Pumain R
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):107-24. PubMed ID: 23001156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.
    Leriche L; Schwartz JC; Sokoloff P
    Neuropharmacology; 2003 Aug; 45(2):174-81. PubMed ID: 12842123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
    Moghaddam B; Krystal JH
    Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate and dopamine components in schizophrenia.
    Seeman P
    J Psychiatry Neurosci; 2009 Mar; 34(2):143-9. PubMed ID: 19270765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antischizophrenic activity independent of dopamine D2 blockade.
    Kalkman HO
    Expert Opin Ther Targets; 2002 Oct; 6(5):571-82. PubMed ID: 12387681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
    Kuepper R; Skinbjerg M; Abi-Dargham A
    Handb Exp Pharmacol; 2012; (212):1-26. PubMed ID: 23129326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia.
    Tseng KY; Lewis BL; Lipska BK; O'Donnell P
    Biol Psychiatry; 2007 Oct; 62(7):730-8. PubMed ID: 17207473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dopamine D3 receptor, a quarter century later.
    Sokoloff P; Le Foll B
    Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain.
    Khan ZU; Gutiérrez A; Martín R; Peñafiel A; Rivera A; De La Calle A
    J Comp Neurol; 1998 Dec; 402(3):353-71. PubMed ID: 9853904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics.
    Joyce JN; Gurevich EV
    Ann N Y Acad Sci; 1999 Jun; 877():595-613. PubMed ID: 10415673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The dopaminergic hypothesis revisited].
    Guillin O
    Encephale; 2006 Oct; 32(5 Pt 4):S908-11; discussion S912. PubMed ID: 17119503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.